Molecular Imaging of Prostate Cancer: Choosing the Right Agent

Steven P Rowe^{1

2}, Martin G Pomper^{3

2}, Michael A Gorin^{3

2}

Affiliations

¹ Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland; and srowe8@jhmi.edu.
² James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
³ Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.

Free article

Comment

Steven P Rowe et al. J Nucl Med. 2018 May.

Free article

. 2018 May;59(5):787-788.

doi: 10.2967/jnumed.117.206318. Epub 2018 Jan 25.

Steven P Rowe^{1

2}, Martin G Pomper^{3

2}, Michael A Gorin^{3

2}

¹ Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland; and srowe8@jhmi.edu.
² James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
³ Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.

No abstract available

Comment on

Comparison of ⁶⁸Ga-PSMA-11 and ¹⁸F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence.
Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F. Calais J, et al. J Nucl Med. 2018 May;59(5):789-794. doi: 10.2967/jnumed.117.203257. Epub 2017 Dec 14. J Nucl Med. 2018. PMID: 29242404 Clinical Trial.